Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
6,713,803
-
Total 13F shares
-
250,540
-
Share change
-
+250,473
-
Total reported value
-
$3,116,718
-
Price per share
-
$12.44
-
Number of holders
-
12
-
Value change
-
+$3,115,885
-
Number of buys
-
11
Institutional Holders of Vivos Therapeutics, Inc. - Common stock, par value $0.0001 per share (VVOS) as of Q4 2023
As of 31 Dec 2023,
Vivos Therapeutics, Inc. - Common stock, par value $0.0001 per share (VVOS) was held by
12 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
250,540 shares.
The largest 10 holders included
Strategic Wealth Investment Group, LLC, ARMISTICE CAPITAL, LLC, Schonfeld Strategic Advisors LLC, VANGUARD GROUP INC, Tower Research Capital LLC (TRC), Newbridge Financial Services Group, Inc., SIGNATUREFD, LLC, GROUP ONE TRADING, L.P., MORGAN STANLEY, and BlackRock Inc..
This page lists
12
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.